专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009059943A1 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS 审中-公开
标题翻译： 4-苄氧基-1-羧氧基 - 哌啶衍生物作为CETP抑制剂用于治疗疾病如高脂血症或类风湿性心脏病
公开(公告)号：WO2009059943A1
公开(公告)日：2009-05-14
申请号：PCT/EP2008/064859
申请日：2008-11-03
申请人： NOVARTIS AG , MOGI, Muneto , YAMADA, Ken , YASOSHIMA, Kayo , KAWANAMI, Toshio , UMEMURA, Ichiro , IWAKI, Yuki , QIN, Hongbo , IMASE, Hidetomo
发明人： MOGI, Muneto , YAMADA, Ken , YASOSHIMA, Kayo , KAWANAMI, Toshio , UMEMURA, Ichiro , IWAKI, Yuki , QIN, Hongbo , IMASE, Hidetomo
IPC分类号： C07D401/12 , C07D401/14 , C07D413/14 , A61K31/5377 , A61P3/06
CPC分类号： C07D401/14 , C07D413/14
摘要： The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
摘要翻译：本发明提供式（I）化合物：其中变体R1，R2，R3，R4，R5，R6，R7如本文所定义，并且其中所述化合物是CETP的抑制剂，因此可用于治疗由CETP介导的或对CETP的抑制作用的疾病或疾病。

2. 发明申请

WO2009071509A1 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS 审中-公开
标题翻译：作为CETP抑制剂的1,2-取代-4-苄氧基 - 吡咯烷衍生物用于治疗疾病如HYPERLI PIDEMIA或ARTERIOSCLEROSIS
公开(公告)号：WO2009071509A1
公开(公告)日：2009-06-11
申请号：PCT/EP2008/066537
申请日：2008-12-01
申请人： NOVARTIS AG , MOGI, Muneto , KAWANAMI, Toshio , YAMADA, Ken , YASOSHIMA, Kayo , IMASE, Hidetomo , MIYAKE, Takahiro , OHMORI, Osamu
发明人： MOGI, Muneto , KAWANAMI, Toshio , YAMADA, Ken , YASOSHIMA, Kayo , IMASE, Hidetomo , MIYAKE, Takahiro , OHMORI, Osamu
IPC分类号： C07D207/14 , C07D403/12 , C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/40 , A61P3/06
CPC分类号： C07D207/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14
摘要： The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
摘要翻译：本发明提供式（I）化合物：其中变体R1，R2，R3，R4，R6，R7如本文所定义，并且其中所述化合物是CETP的抑制剂，因此可用于治疗由CETP介导的疾病或疾病或响应于CETP的抑制。

3. 发明申请

WO2007128568A1 BICYCLIC DERIVATIVES AS CETP INHIBITORS 审中-公开
标题翻译：双酚衍生物作为CETP抑制剂
公开(公告)号：WO2007128568A1
公开(公告)日：2007-11-15
申请号：PCT/EP2007/004058
申请日：2007-05-08
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , KISHIDA, Masashi , MATSUURA, Naoko , IMASE, Hidetomo , IWAKI, Yuki , UMEMURA, Ichiro , OHMORI, Osamu , KAWAHARA, Eiji
发明人： KISHIDA, Masashi , MATSUURA, Naoko , IMASE, Hidetomo , IWAKI, Yuki , UMEMURA, Ichiro , OHMORI, Osamu , KAWAHARA, Eiji
IPC分类号： C07D401/12 , C07D401/14 , C07D471/04 , A61K31/4427 , A61P9/00
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to novel compounds of formula (I): or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.
摘要翻译：本发明涉及新的式（I）化合物：或其药物组合物，其全部变量在本文中定义。本发明还涉及本文中的化合物用于治疗或延缓进展到涉及CETP的疾病的公开。

4. 发明申请

WO2008058967A1 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2008058967A1
公开(公告)日：2008-05-22
申请号：PCT/EP2007/062282
申请日：2007-11-13
申请人： NOVARTIS AG , IMASE, Hidetomo , KISHIDA, Masashi
发明人： IMASE, Hidetomo , KISHIDA, Masashi
IPC分类号： C07D401/12 , C07D401/14 , A61K31/4439 , A61K31/4709 , A61P9/00 , A61P3/00
CPC分类号： C07D401/12 , C07D401/14
摘要： The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
摘要翻译：本发明提供式（I）化合物，所述化合物是CETP的抑制剂，因此可用于治疗CETP介导的病症或疾病或对CETP的抑制作用。

5. 发明申请

WO2007073934A1 PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) 审中-公开
标题翻译：作为胆固醇转运蛋白（CETP）的抑制剂的吡啶胺衍生物
公开(公告)号：WO2007073934A1
公开(公告)日：2007-07-05
申请号：PCT/EP2006/012540
申请日：2006-12-27
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , SAKAKI, Junichi , KISHIDA, Masashi , MATSUURA, Naoko , UMEMURA, Ichiro , KAWAHARA, Eiji , YAMADA, Ken , KONISHI, Kazuhide , IWAKI, Yuki , IMASE, Hidetomo , MIYAKE, Takahiro
发明人： SAKAKI, Junichi , KISHIDA, Masashi , MATSUURA, Naoko , UMEMURA, Ichiro , KAWAHARA, Eiji , YAMADA, Ken , KONISHI, Kazuhide , IWAKI, Yuki , IMASE, Hidetomo , MIYAKE, Takahiro
IPC分类号： C07D213/38 , C07D213/40 , C07D401/12 , A61K31/44 , A61K31/4439 , A61P3/00 , A61P9/00
CPC分类号： C07D401/12 , C07D213/74 , C07D401/14 , C07D405/14 , C07D409/14
摘要： The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are as defined, useful as inhibitors of chlosteryl ester transfer protein.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的盐，其中变量如上所定义，可用作chlosteryl ester transfer protein的抑制剂。

6. 发明申请

WO2016203432A1 ANTIBODY DRUG CONJUGATES 审中-公开
标题翻译：抗体药物联合用药
公开(公告)号：WO2016203432A1
公开(公告)日：2016-12-22
申请号：PCT/IB2016/053595
申请日：2016-06-17
申请人： NOVARTIS AG , ABRAMS, Tinya , COHEN, Steven , D'ALESSIO, Joseph Anthony , DAMIANO, Jason , DURR, Clemens , GEIERSTANGER, Bernhard Hubert , HU, Qi-Ying , HUBER, Thomas , IMASE, Hidetomo , JIN, Yunho , MENEZES, Daniel , MILLER, Kathy , MOHSENI, Morvarid , OU, Weijia , RENDAHL, Katherine , UNO, Tetsuo , WAN, Yongqin , WANG, Xing
发明人： ABRAMS, Tinya , COHEN, Steven , D'ALESSIO, Joseph Anthony , DAMIANO, Jason , DURR, Clemens , GEIERSTANGER, Bernhard Hubert , HU, Qi-Ying , HUBER, Thomas , IMASE, Hidetomo , JIN, Yunho , MENEZES, Daniel , MILLER, Kathy , MOHSENI, Morvarid , OU, Weijia , RENDAHL, Katherine , UNO, Tetsuo , WAN, Yongqin , WANG, Xing
IPC分类号： C07K16/28 , A61K47/48 , A61K31/00 , A61K39/395 , A61P35/00
CPC分类号： C07K16/28 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
摘要翻译：本申请公开了抗P-钙粘蛋白抗体，其抗原结合片段和所述抗体或抗原结合片段的抗体药物偶联物，特别是抗体药物偶联物，其包含缀合于奥司他丁类似物的抗P-钙粘蛋白抗体。本发明还涉及使用抗体药物偶联物治疗癌症的方法。本文还公开了制备抗体，抗原结合片段和抗体药物缀合物的方法，以及使用抗体和抗原结合片段作为诊断试剂的方法。

7. 发明申请

WO2015079376A1 METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES 审中-公开
标题翻译：用于与酮改性聚合物结合的方法
公开(公告)号：WO2015079376A1
公开(公告)日：2015-06-04
申请号：PCT/IB2014/066300
申请日：2014-11-24
申请人： NOVARTIS AG , HU, Qi-Ying , IMASE, Hidetomo
发明人： HU, Qi-Ying , IMASE, Hidetomo
IPC分类号： A61K47/48
CPC分类号： A61K47/48038 , A61K47/542 , A61K47/62 , A61K47/646 , A61K47/68 , A61K47/6803 , A61K47/6849 , C07K1/1133 , C07K7/64 , C07K2317/40
摘要： The invention provides improved methods to prepare protein conjugates from a ketone-modified protein. In one embodiment, the protein is prepared by linking two free cysteines by reaction with a 1,3-dihaloacetone or similar ketone-containing reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form an oxime, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant, and the new ketone is used to form an oxime with a suitable payload molecule, thus conjugating the protein to a payload. The method provides improved reaction conditions for the oxime formation, whereby higher yields and Improved product homogeneity are achieved.
摘要翻译：本发明提供了从酮修饰的蛋白质制备蛋白质缀合物的改进方法。在一个实施方案中，通过与1,3-二卤代丙酮或类似的含酮反应物反应连接两个游离半胱氨酸来制备蛋白质，其将两个半胱氨酸的硫原子连接在一起。然后将插入硫原子之间的酮用于形成肟，从而使蛋白质与有效载荷共轭。在另一个实施方案中，通过与1,3-二卤代丙酮或类似的反应物反应将两个半胱氨酸残基连接在一起，并且新的酮用于形成具有合适有效载荷分子的肟，从而将蛋白质与有效载荷共轭。该方法为肟形成提供改进的反应条件，从而获得更高的产率和改进的产物均匀性。

8. 发明申请

WO2011061168A1 ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS 审中-公开
标题翻译： ARYL-吡啶衍生物作为醛固酮合成酶抑制剂
公开(公告)号：WO2011061168A1
公开(公告)日：2011-05-26
申请号：PCT/EP2010/067536
申请日：2010-11-16
申请人： NOVARTIS AG , ALLAN, Martin , CHAMOIN, Sylvie , HU, Qi-Ying , IMASE, Hidetomo , PAPILLON, Julien
发明人： ALLAN, Martin , CHAMOIN, Sylvie , HU, Qi-Ying , IMASE, Hidetomo , PAPILLON, Julien
IPC分类号： C07D213/30 , C07D213/57 , C07D213/61 , C07D401/04 , C07D405/04 , C07D409/04 , A61K31/44 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61P9/12
CPC分类号： C07D213/57 , C07D213/30 , C07D213/61 , C07D401/04 , C07D405/04 , C07D409/04
摘要： The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are defined herein. The invention also relates to a method for manufacturing compounds of the invention, and their therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要翻译：本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和n如本文所定义。本发明还涉及制备本发明化合物的方法及其治疗用途。本发明还提供药理活性剂和药物组合物的组合。

9. 发明申请

WO2014083505A1 METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS 审中-公开
标题翻译：从含有蛋白质的蛋白质制备结合物的方法
公开(公告)号：WO2014083505A1
公开(公告)日：2014-06-05
申请号：PCT/IB2013/060427
申请日：2013-11-26
申请人： NOVARTIS AG , HU, Qi-Ying , IMASE, Hidetomo
发明人： HU, Qi-Ying , IMASE, Hidetomo
IPC分类号： A61K47/48
CPC分类号： A61F5/0006 , A61C5/90 , A61F5/566 , A61K47/542 , A61K47/6415 , A61K47/646 , A61K47/6803 , A61K47/6849
摘要： The invention provides methods to prepare protein conjugates from proteins having at least two cysteines. In one embodiment, a protein with a disulfide linkage is reduced to provide two free cysteines for reaction with a 1,3-dihaloacetone or similar reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form a Schiff base to an aminated payload molecule, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant. The linkage between the sulfur atoms in each case holds the protein or peptide in a constrained conformation, while also providing a convenient place for attaching a payload with good specificity and efficiency.
摘要翻译：本发明提供了从具有至少两个半胱氨酸的蛋白质制备蛋白质缀合物的方法。在一个实施方案中，具有二硫键的蛋白质被还原以提供两个游离半胱氨酸，用于与1,3-二卤代丙酮或类似的反应物反应，将两个半胱氨酸的硫原子连接在一起。然后将插入硫原子之间的酮用于形成胺化有效载体分子的席夫碱，从而将蛋白质与有效载荷共轭。在另一个实施方案中，通过与1,3-二卤代丙酮或类似的反应物反应将两个半胱氨酸残基连接在一起。每种情况下硫原子之间的连接将蛋白质或肽保持在约束的构象中，同时也提供了一种方便的附着有效载荷的特点和效率的地方。

10. 发明申请

WO2008058961A1 HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS 审中-公开
标题翻译：杂环衍生物作为CETP抑制剂
公开(公告)号：WO2008058961A1
公开(公告)日：2008-05-22
申请号：PCT/EP2007/062274
申请日：2007-11-13
申请人： NOVARTIS AG , IMASE, Hidetomo , KISHIDA, Masashi
发明人： IMASE, Hidetomo , KISHIDA, Masashi
IPC分类号： C07D401/12 , C07D401/14 , A61K31/4427
CPC分类号： C07D401/12
摘要： The present invention provides a compound of formula (I), said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
摘要翻译：本发明提供式（I）化合物，所述化合物是CETP的抑制剂，因此可用于治疗CETP介导的病症或疾病或对CETP的抑制作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式